Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
European Urology Oncology|July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate CancerNiven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
European Urology|January 19, 2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT TrialRobert J Motzer, Paul Russo, Naomi Haas, et al.
European Urology|January 18, 2025
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety AnalysisSilke Gillessen, Bertrand Tombal, Fabio Turco, et al.
Anticancer Research|March 9, 2012
Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancerPetteri Hervonen, Heikki Joensuu, Timo Joensuu, et al.
Nature Communications|October 6, 2025
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancerMing Lei, Michael J Overman, Jin Yao, et al.
NPJ Genomic Medicine|May 29, 2024
Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patientsTom Venken, Ian S Miller, Ingrid Arijs, et al.
Cancer|September 28, 2023
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomasShivaani Kummar, Lin Shen, David S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 TrialDaniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
Plos One|December 18, 2020
Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trialLauren Brady, Brian Hayes, Gráinne Sheill, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 22, 2023
ExPeCT: a randomised trial examining the impact of exercise on quality of life in men with metastatic prostate cancerGráinne Sheill, Lauren Brady, Brian Hayes, et al.
Pageof 10